|
Development-stage Alfacell may kiss a few frogs in hopes one will transform into a princely product. The biotechnology firm has isolated proteins from Northern Leopard frog eggs and embryos as possible therapies for cancerous tumors that have become resistant to chemotherapy. The company's lead drug candidate, Onconase, is in late-stage clinical trials to treat mesothelioma, a cancer afflicting the lungs and stomach caused by exposure to asbestos. Alfacell is researching applications for Onconase and other amphibian proteins for applications in other areas of oncology, including small-cell lung cancer, as well as infectious diseases that include HIV.
|
| | | Contact Information | |
Address: |
300 Atrium Dr.
Somerset, NJ 08873
| | Phone: | 732-652-4525 | | Fax: | 732-652-4575 |
|
| Financial
Highlights | | Fiscal Year End: | July | | Revenue (2008): | 0.00 M | | Employees (2008): | 15 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman:
David Sidransky
| | • |
President, COO, and CFO:
Charles Muniz
| | • |
SVP Commercial Development and Operations:
Andrew P. Aromando
|
|
|
